Photo from Jeff Ryckman/Twitter
Nov 30, 2023, 12:31
Jeff Ryckman: Omitting RT in bulky early-stage cHL
Jeff Ryckman, Radiation Oncologist and Assistant Professor at West Virginia University, shared the following post on LinkedIn:
“CALGB50801: Omitting RT in bulky (>10 cm or 1/3 the maximum intrathoracic diameter) early-stage cHL
- Omits RT at expense of 2 addnl cycles of ABVD.
- Does not discuss the degree of CT-based residual.
- Utilized outdated RT methods (IFRT) in SER.
- Each cycle of ABVD is equivalent to 5 Gy mean heart dose (MHD) – EORTC-LYSA: View it here.
- CALGB50801 “delivers” 10 Gy MHD by omitting RT and replacing it with adria x2c:
- CCSS St. Jude CV Risk calculator
Why does RT-free survival continue to be a thing with modern RT techniques?
Protons most useful if below L main coronary A or mediastinum+axilla in young female
TL;DR Addn’l Adriamycin is not benign! Modern RT techniques have come a long way.”
For the article click here.
Source: Jeff Ryckman/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 09:39
Nov 13, 2024, 08:59